

ORAL PRESENTATION

Open Access

# Melanoma-intrinsic $\beta$ -catenin signaling prevents T cell infiltration and anti-tumor immunity

Stefani Spranger\*, Riyue Bao, Thomas Gajewski

From Society for Immunotherapy of Cancer 29th Annual Meeting  
National Harbor, MD, USA. 6-9 November 2014

A subset of melanoma patients has evidence for spontaneous anti-tumor immune responses and T cell infiltration into tumor sites, which has important prognostic value and is associated with clinical responses to immunotherapies. However, the molecular mechanisms explaining absence of a T cell response in the majority of patients are not defined. Analyses of human melanoma metastases by exome sequencing, gene expression profiling, and IHC have revealed that many tumors that lack a T cell signature show alterations in the Wnt/ $\beta$ -catenin signaling pathway. To investigate if constitutively active  $\beta$ -catenin signaling within the tumor cells might inhibit immune responses, we utilized an inducible autochthonous mouse melanoma model driven by inducible  $\text{Braf}^{\text{V600E}}$  and PTEN-deletion, with or without inducible expression of active  $\beta$ -catenin. While  $\text{Braf}/\text{PTEN}$  melanomas showed presence of a modest T cell infiltrate, T cells were nearly completely eliminated in tumors expressing active  $\beta$ -catenin. The T cells that were present in the  $\text{Braf}/\text{PTEN}$  tumors showed an exhausted phenotype as what has been seen in transplanted tumor models, and therapeutic efficacy of combination therapy using  $\alpha\text{CTLA4}$  with  $\alpha\text{PD-L1}$  mAbs was limited to  $\text{Braf}/\text{PTEN}$  tumors. To test whether the lack of T cell infiltration was due to a defect in early T cell priming, these mice were additionally bred to inducibly express the SIY model antigen within the developing tumors. Adoptive transfer of 2C TCR Tg SIY-specific T cells revealed defective spontaneous T cell priming when tumors expressed active  $\beta$ -catenin. Analysis of the antigen-presenting cell compartment revealed a selective decrease in the  $\text{CD103}^+$  DC subset within the tumor microenvironment, and T cell infiltration could be restored by intra-tumoral injection of FLT3-ligand-derived dendritic cells. The lack of  $\text{CD103}^+$  dermal dendritic cells was associated with reduced expression of the chemokines

CCL4 and CXCL1. Surprisingly we identified that tumor cells themselves as the major chemokine source in  $\text{Braf}/\text{PTEN}$  tumors, while tumors with active  $\beta$ -catenin signaling lacked expression of those chemokines. Therefore, our data have identified the first defined molecular pathway in tumor cells that results in defective spontaneous anti-tumor T cell responses, an observation with important implications for cancer immunotherapy.

## Consent

Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Published: 6 November 2014

doi:10.1186/2051-1426-2-S3-O15

**Cite this article as:** Spranger et al.: Melanoma-intrinsic  $\beta$ -catenin signaling prevents T cell infiltration and anti-tumor immunity. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):O15.

## Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



University of Chicago, Chicago, IL, USA



© 2014 Spranger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.